search
Back to results

Single Dose of Clonazepam Versus Intermiittent Diazepam for Febrile Seizures Prevention

Primary Purpose

Recurrent Febrile Convulsion

Status
Unknown status
Phase
Not Applicable
Locations
Thailand
Study Type
Interventional
Intervention
Clonazepam 0.5 MG
Diazepam Tablets
Sponsored by
Queen Sirikit National Institute of Child Health
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Recurrent Febrile Convulsion focused on measuring recurrent febrile convulsions, Clonazepam, prophylaxis

Eligibility Criteria

6 Months - 60 Months (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • age 6-60 months at date of enrollment
  • 3 or more episodes of clinically diagnosed febrile seizures

Exclusion Criteria:

  • history of afebrile seizures or any history suggested the epilepsy
  • history of previous brain insults; CNS infection, birth trauma, traumatic brain injury.
  • delayed developmental milestones
  • abnormal neurological examinations
  • currently treatment by continous antiepileptic drug(s)
  • A contraindication to Clonazepam, Diazepam such as drug hypersensitivity, liver disease.
  • Predictable lack of available of follow up.

Sites / Locations

  • Queen Sirikit National Institute of Child HealthRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Single dose Clonazepam

Intermittent oral diazepam

Arm Description

Clonazepam(0.5 mg/tablet) 0.02 mg/kg orally once at the time of fever present. (body temperature more than 38 degree Celsius)

Diazepam 0.3 mg/kg every 8 hours for 3 doses. (24 hr) start at the time of body temperature more than 38 degree Celsius.

Outcomes

Primary Outcome Measures

Recurrent rate of febrile seizures
Rate of seizure occurs when the children have febrile illnesses (at the onset of fever until fever gone). The seizures will be reported by their parents/caregivers. (via the seizure record form and the interview.) Statistic analysis: Cumulative incidence (person-year). percent. Comparison between the two group by unpaired t test.

Secondary Outcome Measures

Number of participants with adverse reaction of medications
The adverse reactions will be recorded by their caregivers in the record form for 7 days since patients taking the medication (clonapam or diazepam). The adverse reactions are drowsiness, ataxia, irritability, drooling, insomnia and rashes. Statistic analysis: cumulative incidence (person-year), Comparison between the two group by unpaired t test.
Associated factors: Sex
To evaluate the associated factors of multiple recurrent febrile seizures. The data will be collected in the record form by the primary investigator at the enrollment. Statistic analysis: comparison between group by chi square
Associated factors: age at first febrile seizure
To evaluate the associated factors of multiple recurrent febrile seizures. The data will be collected in the record form by interviewing the caregivers to recall the information. Statistic analysis: comparison between group by unpaired t test
Associated factors: the lowest temperature that cause seizure
To evaluate the associated factors of multiple recurrent febrile seizures. The data will be collected in the record form by interviewing the caregivers to recall the information. Statistic analysis: comparison between group by unpaired t test
Number of participants with febrile convulsions in parents or siblings
To evaluate the associated factors of multiple recurrent febrile seizures. The data will be collected in the record form by interviewing the caregivers. Statistic analysis: comparison between group by chi square
Number of participants with epilepsy in parents or siblings
To evaluate the associated factors of multiple recurrent febrile seizures. The data will be collected in the record form by interviewing the caregivers. Statistic analysis: comparison between group by chi square
Number of participants with type of febrile seizures (simple or complex)
To evaluate the associated factors of multiple recurrent febrile seizures. Type of febrile seizure simple: seizure duration less than 15 min, generalized seizures, one seizure in 24 hours complex:15 minutes or more and/or focal seizures and/or 2 or more seizures in 24 hours The data will be collected in the record form by interviewing the caregivers. Statistic analysis: comparison between group by chi square
Number of participants with delayed developmental milestones
The data will be collected by the developmental screening tools; Age and Stages Questionaires, third edition reported by the caregivers. Scoring will be done by neurology pediatrician at the enrollment. Age and Stages Questionaires(third editon) are divided in 5 areas; communication, gross motor, fine motor, problem solving, personal-social, each area has 6 questions. Scores for each area are between 0 to 60. The Cutoff points are different in each area. If the score is above the cutoff, the children development appears normal for age. (The cutoff for communication is 29.65, Gross motor is 22.25, fine motor is 25.14, problem solving is 27.72 and personal-social is 25.34) Statistic analysis: comparison between group by unpaired t test

Full Information

First Posted
April 5, 2020
Last Updated
August 24, 2021
Sponsor
Queen Sirikit National Institute of Child Health
search

1. Study Identification

Unique Protocol Identification Number
NCT04364321
Brief Title
Single Dose of Clonazepam Versus Intermiittent Diazepam for Febrile Seizures Prevention
Official Title
The Efficacy of A Single Dose Clonazepam Compared With the Intermittent Diazepam to Prevent Recurrent Febrile Seizures in Queen Sirikit National Institute of Child Health
Study Type
Interventional

2. Study Status

Record Verification Date
August 2021
Overall Recruitment Status
Unknown status
Study Start Date
May 13, 2020 (Actual)
Primary Completion Date
June 2023 (Anticipated)
Study Completion Date
June 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Queen Sirikit National Institute of Child Health

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
To study the efficacy and safety of single dose clonazepam compared with intermittent oral diazepam for prevention of recurrent febrile seizures in children who had three or more febrile seizures.
Detailed Description
Febrile seizures are the most common type of seizures disorder of young children. The risk of recurrences are 33 percent overall, half of them had at least one recurrent seizure (the 3rd febrile seizures). After that the recurrent rate is 50-100 percent depend on their risk factors. A few studies found that multiple recurrent febrile seizures might associated with language developmental delayed, poor speed performance quotient, Attention deficit hyperactivity disorders. Moreover, seizures are upsetting both parents and children. During the febrile illness, the intermittent diazepam, continuous phenobarbital and valproate are effective for prevention of the recurrences. Because of the benign nature of a simple febrile seizures, the risks of side effects generally outweigh the benefits. However, there is no clinical guidelines for prevention of recurrent febrile seizures in the children who experienced multiple occurrences. The better prophylactic drug; safe, effective and easy to use, for prevention of recurrent febrile seizures in children with multiple recurrences might be needed. Clonazepam, the long half-life benzodiazepine, is commonly used for treatment of epilepsy may be effective in preventing recurrent febrile seizures. This study, a single-blind, randomized clinical trial, single dose clonazepam at the time of fever present compared with oral diazepam during the fever to prevent the recurrent febrile seizures.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Recurrent Febrile Convulsion
Keywords
recurrent febrile convulsions, Clonazepam, prophylaxis

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
A pragmatic parallel group randomized trial comparing single dose clonazepam with intermittent oral diazepam for prevention recurrent febrile seizures
Masking
Care ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
74 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Single dose Clonazepam
Arm Type
Experimental
Arm Description
Clonazepam(0.5 mg/tablet) 0.02 mg/kg orally once at the time of fever present. (body temperature more than 38 degree Celsius)
Arm Title
Intermittent oral diazepam
Arm Type
Active Comparator
Arm Description
Diazepam 0.3 mg/kg every 8 hours for 3 doses. (24 hr) start at the time of body temperature more than 38 degree Celsius.
Intervention Type
Drug
Intervention Name(s)
Clonazepam 0.5 MG
Other Intervention Name(s)
Rivotril, Povanil
Intervention Description
Clonazepam 0.02 mg/kg only one dose
Intervention Type
Drug
Intervention Name(s)
Diazepam Tablets
Intervention Description
Diazepam 0.3 mg/kg every 8 hours for 3 doses. (24 hr)
Primary Outcome Measure Information:
Title
Recurrent rate of febrile seizures
Description
Rate of seizure occurs when the children have febrile illnesses (at the onset of fever until fever gone). The seizures will be reported by their parents/caregivers. (via the seizure record form and the interview.) Statistic analysis: Cumulative incidence (person-year). percent. Comparison between the two group by unpaired t test.
Time Frame
the assessment will be done at 12 months after enrollment
Secondary Outcome Measure Information:
Title
Number of participants with adverse reaction of medications
Description
The adverse reactions will be recorded by their caregivers in the record form for 7 days since patients taking the medication (clonapam or diazepam). The adverse reactions are drowsiness, ataxia, irritability, drooling, insomnia and rashes. Statistic analysis: cumulative incidence (person-year), Comparison between the two group by unpaired t test.
Time Frame
7 days
Title
Associated factors: Sex
Description
To evaluate the associated factors of multiple recurrent febrile seizures. The data will be collected in the record form by the primary investigator at the enrollment. Statistic analysis: comparison between group by chi square
Time Frame
at the enrollment.
Title
Associated factors: age at first febrile seizure
Description
To evaluate the associated factors of multiple recurrent febrile seizures. The data will be collected in the record form by interviewing the caregivers to recall the information. Statistic analysis: comparison between group by unpaired t test
Time Frame
at the enrollment
Title
Associated factors: the lowest temperature that cause seizure
Description
To evaluate the associated factors of multiple recurrent febrile seizures. The data will be collected in the record form by interviewing the caregivers to recall the information. Statistic analysis: comparison between group by unpaired t test
Time Frame
at the enrollment.
Title
Number of participants with febrile convulsions in parents or siblings
Description
To evaluate the associated factors of multiple recurrent febrile seizures. The data will be collected in the record form by interviewing the caregivers. Statistic analysis: comparison between group by chi square
Time Frame
at the enrollment.
Title
Number of participants with epilepsy in parents or siblings
Description
To evaluate the associated factors of multiple recurrent febrile seizures. The data will be collected in the record form by interviewing the caregivers. Statistic analysis: comparison between group by chi square
Time Frame
at the enrollment.
Title
Number of participants with type of febrile seizures (simple or complex)
Description
To evaluate the associated factors of multiple recurrent febrile seizures. Type of febrile seizure simple: seizure duration less than 15 min, generalized seizures, one seizure in 24 hours complex:15 minutes or more and/or focal seizures and/or 2 or more seizures in 24 hours The data will be collected in the record form by interviewing the caregivers. Statistic analysis: comparison between group by chi square
Time Frame
at the enrollment.
Title
Number of participants with delayed developmental milestones
Description
The data will be collected by the developmental screening tools; Age and Stages Questionaires, third edition reported by the caregivers. Scoring will be done by neurology pediatrician at the enrollment. Age and Stages Questionaires(third editon) are divided in 5 areas; communication, gross motor, fine motor, problem solving, personal-social, each area has 6 questions. Scores for each area are between 0 to 60. The Cutoff points are different in each area. If the score is above the cutoff, the children development appears normal for age. (The cutoff for communication is 29.65, Gross motor is 22.25, fine motor is 25.14, problem solving is 27.72 and personal-social is 25.34) Statistic analysis: comparison between group by unpaired t test
Time Frame
at the enrollment.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
60 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: age 6-60 months at date of enrollment 3 or more episodes of clinically diagnosed febrile seizures Exclusion Criteria: history of afebrile seizures or any history suggested the epilepsy history of previous brain insults; CNS infection, birth trauma, traumatic brain injury. delayed developmental milestones abnormal neurological examinations currently treatment by continous antiepileptic drug(s) A contraindication to Clonazepam, Diazepam such as drug hypersensitivity, liver disease. Predictable lack of available of follow up.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jinjutha Nithiuthai, MD
Phone
66806218033
Email
jinjutha.nt@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Sirorat Suwannachote, MD
Phone
6623548333
Email
sirorat.s@rsu.ac.th
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jinjutha Nithiuthai, MD
Organizational Affiliation
Queen Sirikit National Institute of Child Health
Official's Role
Principal Investigator
Facility Information:
Facility Name
Queen Sirikit National Institute of Child Health
City
Ratchathewi
State/Province
Bangkok
ZIP/Postal Code
10400
Country
Thailand
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jinjutha Nithiuthai, MD
Email
jinjutha.nt@gmail.com
First Name & Middle Initial & Last Name & Degree
Jinjutha Nitiuthai, MD
First Name & Middle Initial & Last Name & Degree
Somjit Sri-udomkajorn, MD
First Name & Middle Initial & Last Name & Degree
Sirorat Suwannachote, MD

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
There is no plan to make IPD available due to the confidentiality.
Citations:
PubMed Identifier
9111436
Citation
Berg AT, Shinnar S, Darefsky AS, Holford TR, Shapiro ED, Salomon ME, Crain EF, Hauser AW. Predictors of recurrent febrile seizures. A prospective cohort study. Arch Pediatr Adolesc Med. 1997 Apr;151(4):371-8. doi: 10.1001/archpedi.1997.02170410045006.
Results Reference
background
PubMed Identifier
2137875
Citation
Berg AT, Shinnar S, Hauser WA, Leventhal JM. Predictors of recurrent febrile seizures: a metaanalytic review. J Pediatr. 1990 Mar;116(3):329-37. doi: 10.1016/s0022-3476(05)82816-1.
Results Reference
background
PubMed Identifier
9851235
Citation
Kolfen W, Pehle K, Konig S. Is the long-term outcome of children following febrile convulsions favorable? Dev Med Child Neurol. 1998 Oct;40(10):667-71. doi: 10.1111/j.1469-8749.1998.tb12326.x.
Results Reference
background
PubMed Identifier
22937894
Citation
Visser AM, Jaddoe VW, Ghassabian A, Schenk JJ, Verhulst FC, Hofman A, Tiemeier H, Moll HA, Arts WF. Febrile seizures and behavioural and cognitive outcomes in preschool children: the Generation R study. Dev Med Child Neurol. 2012 Nov;54(11):1006-11. doi: 10.1111/j.1469-8749.2012.04405.x. Epub 2012 Sep 3.
Results Reference
background
PubMed Identifier
27412639
Citation
Bertelsen EN, Larsen JT, Petersen L, Christensen J, Dalsgaard S. Childhood Epilepsy, Febrile Seizures, and Subsequent Risk of ADHD. Pediatrics. 2016 Aug;138(2):e20154654. doi: 10.1542/peds.2015-4654. Epub 2016 Jul 13.
Results Reference
background
PubMed Identifier
31618476
Citation
Billstedt E, Nilsson G, Leffler L, Carlsson L, Olsson I, Fernell E, Gillberg C. Cognitive functioning in a representative cohort of preschool children with febrile seizures. Acta Paediatr. 2020 May;109(5):989-994. doi: 10.1111/apa.15059. Epub 2019 Nov 10.
Results Reference
background
PubMed Identifier
8510706
Citation
Rosman NP, Colton T, Labazzo J, Gilbert PL, Gardella NB, Kaye EM, Van Bennekom C, Winter MR. A controlled trial of diazepam administered during febrile illnesses to prevent recurrence of febrile seizures. N Engl J Med. 1993 Jul 8;329(2):79-84. doi: 10.1056/NEJM199307083290202.
Results Reference
result
PubMed Identifier
3907504
Citation
Knudsen FU. Recurrence risk after first febrile seizure and effect of short term diazepam prophylaxis. Arch Dis Child. 1985 Nov;60(11):1045-9. doi: 10.1136/adc.60.11.1045.
Results Reference
result
PubMed Identifier
19125841
Citation
Capovilla G, Mastrangelo M, Romeo A, Vigevano F. Recommendations for the management of "febrile seizures": Ad Hoc Task Force of LICE Guidelines Commission. Epilepsia. 2009 Jan;50 Suppl 1:2-6. doi: 10.1111/j.1528-1167.2008.01963.x.
Results Reference
result
PubMed Identifier
28225210
Citation
Offringa M, Newton R, Cozijnsen MA, Nevitt SJ. Prophylactic drug management for febrile seizures in children. Cochrane Database Syst Rev. 2017 Feb 22;2(2):CD003031. doi: 10.1002/14651858.CD003031.pub3.
Results Reference
result
Links:
URL
http://journals.sbmu.ac.ir/ijcn/article/view/1868
Description
Intermittent Clonazepam in the prevention of recurrent febrile seiziures

Learn more about this trial

Single Dose of Clonazepam Versus Intermiittent Diazepam for Febrile Seizures Prevention

We'll reach out to this number within 24 hrs